BEGIN:VCALENDAR VERSION:2.0 PRODID:-//http://www.ucmr.umu.se//NONSGML kigkonsult.se iCalcreator 2.29.29 // CALSCALE:GREGORIAN METHOD:PUBLISH UID:34f7c7c4-6acb-467d-930e-40798dac8e2b X-WR-CALNAME:JCal Pro Calendar X-WR-CALDESC:Your online events calendar X-WR-TIMEZONE:Europe/Stockholm BEGIN:VTIMEZONE TZID:Europe/Stockholm BEGIN:STANDARD TZNAME:CET DTSTART:20251026T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 RDATE:20261025T030000 RDATE:20271031T030000 END:STANDARD BEGIN:DAYLIGHT TZNAME:CEST DTSTART:20260329T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 RDATE:20270328T020000 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT UID:aa7e0f6e0cec59f4edf93a20e2ef56dbhttp://www.ucmr.umu.se DTSTAMP:20260625T195216Z CATEGORIES:Seminar DESCRIPTION:Department of Clinical Microbiology

Extra Seminar
Title:
Resolving the stage-specific contribution of the anti-apopt otic proteins to humoral immunity

Ingela Vikström

Wa lter and Eliza Hall Institute
Melbourne\, Australia

Place: Betula\, University Hospital\, building 6 M

-----------
< br />Dr Ingela Vikström completed her PhD at the Dept. Med Biosciences\, U meå University in 2006. She then relocated to Melbourne Australia were she is currently a post doctoral fellow at the Walter and Eliza Hall Institut e. Some of her recent publications include:

Vikstrom I\, Tarlin ton DM. B cell memory and the role of apoptosis in its formation. Mol Immu nol. 2011 48:1301-6.
Vikstrom I\, Carotta S\, Lüthje K\, Peperzak V\ , Jost PJ\, Glaser S\, Busslinger M\, Bouillet P\, Strasser A\, Nutt SL\, Tarlinton DM. Mcl-1 is essential for germinal center formation and B cell memory. Science. 2010 330:1095-9
Carrington EM\, Vikstrom IB\, Light A\, Sutherland RM\, Londrigan SL\, Mason KD\, Huang DC\, Lew AM\, Tarlinto n DM. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins rep resent another class of selective immune modulatory drugs. Proc Natl Acad Sci U S A. 2010 107:10967-71.



DTSTART;TZID=Europe/Stockholm:20111221T140000 DTEND;TZID=Europe/Stockholm:20111221T150000 SUMMARY:Seminar - Ingela Vikström: Resolving the stage-specific contributio n of the anti-apoptotic proteins to humoral immunity URL:http://www.ucmr.umu.se/about-ucmr/events/162-ucmr-calendar/164-seminar/ 155-seminar-ingela-vikstroem-resolving-the-stage-specific-contribution-of- the-anti-apoptotic-proteins-to-humoral-immunity.html X-ALT-DESC;FMTTYPE=TEXT/HTML:Department of Clinical Microbiology

Extra Seminar
Title:
Resolving the stage-specific contribution of the anti-apoptotic proteins to humoral immunity

Ingela Vikst röm

Walter and Eliza Hall Institute
Melbourne\, Australia< br />
Place: Betula\, University Hospital\, building 6 M

- ----------

Dr Ingela Vikström completed her PhD at the Dept. Me d Biosciences\, Umeå University in 2006. She then relocated to Melbourne A ustralia were she is currently a post doctoral fellow at the Walter and El iza Hall Institute. Some of her recent publications include:

Vi kstrom I\, Tarlinton DM. B cell memory and the role of apoptosis in its fo rmation. Mol Immunol. 2011 48:1301-6.
Vikstrom I\, Carotta S\, Lüthj e K\, Peperzak V\, Jost PJ\, Glaser S\, Busslinger M\, Bouillet P\, Strass er A\, Nutt SL\, Tarlinton DM. Mcl-1 is essential for germinal center form ation and B cell memory. Science. 2010 330:1095-9
Carrington EM\, Vik strom IB\, Light A\, Sutherland RM\, Londrigan SL\, Mason KD\, Huang DC\, Lew AM\, Tarlinton DM. BH3 mimetics antagonizing restricted prosurvival B cl-2 proteins represent another class of selective immune modulatory drugs . Proc Natl Acad Sci U S A. 2010 107:10967-71.



END:VEVENT BEGIN:VEVENT UID:9f3e4d7f1163f9514468536793ef5202http://www.ucmr.umu.se DTSTAMP:20260625T195216Z CATEGORIES:Seminar DESCRIPTION:

Department of Clinical Microbiology
Extra Seminar
Title:
High-Throughput Screening in an Academic Setting\, a Bona Fide Path to Novel Therapeutics and Tool Molecules?

\n

Speaker:
Kurt Lackovic

Walter and Eli za Hall Institute Melbourne\, Australia
Place: Betula\, Univ ersity Hospital\, building 6 M


The Walter and E liza Hall Institute of Medical Research was one of the first academic inst itutions in the world to establish a high-throughput screening facility. H ow this Facility operates\, along with the format of projects\, outcomes t o date\, examples of projects\, and recent expansion to include high-conte nt screening will be discussed.

\n

 

\n

Biography Paragraph:

\n

Dr Kurt Lackovic completed his PhD in analytical chemistry in 2003. H e then relocated to Sweden for his initial post doctoral placement\, at th e Department of Medical Biosciences\, Umeå University\, Sweden. Dr Lackovi c returned to Melbourne in October 2006\, immediately taking a position in the WEHI High-Throughput Chemical Screening (HTCS) Facility. In his curre nt role\, Dr Lackovic is responsible for managing collaborative research p rojects seeking lead-like molecules across a broad range of target classes and disease types\, developing novel techniques\, and reporting findings. In addition\, he is responsible for the HTCS Facility's high-content imag ing capabilities.

\n


Recent publications include:
Croker et al. Fas-mediated neutrophil apoptosis is accelerated by Bid\, Bak\, and Bax and inhibited by Bcl-2 and Mcl-1. Proc Natl AcadSci U S A. 2011 108:13135-40.
Lackovic K\, Parisot JP\, Sleebs N\, Bae ll JB\, Debien L\, Watson KG\, Curtis JM\,Handman E\, Street IP\, Kedziers ki L. Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small-molecule chemical library. Antimicrob Agents Chemother. 2010 54:1712-9.

DTSTART;TZID=Europe/Stockholm:20111222T140000 DTEND;TZID=Europe/Stockholm:20111222T150000 SUMMARY:Seminar- Kurt Lackovic: High-Throughput Screening in an Academic Se tting\, a Bona Fide Path to Novel Therapeutics and Tool Molecules? URL:http://www.ucmr.umu.se/about-ucmr/events/162-ucmr-calendar/164-seminar/ 157-seminar-kurt-lackovic-high-throughput-screening-in-an-academic-setting -a-bona-fide-path-to-novel-therapeutics-and-tool-molecules.html X-ALT-DESC;FMTTYPE=TEXT/HTML:

Department of Clinical Microbiology
E xtra Seminar
Title:
High-Throughput Screening in an Ac ademic Setting\, a Bona Fide Path to Novel Therapeutics and Tool Molecules ?

\n

Speaker:
Kurt Lackovic

Walter and Eliza Hall Institute Melbourne\, Australia
Pla ce: Betula\, University Hospital\, building 6 M


The Walter and Eliza Hall Institute of Medical Research was one of the fi rst academic institutions in the world to establish a high-throughput scre ening facility. How this Facility operates\, along with the format of proj ects\, outcomes to date\, examples of projects\, and recent expansion to i nclude high-content screening will be discussed.

\n

 

\n

Biograp hy Paragraph:

\n

Dr Kurt Lackovic completed his PhD in analytical che mistry in 2003. He then relocated to Sweden for his initial post doctoral placement\, at the Department of Medical Biosciences\, Umeå University\, S weden. Dr Lackovic returned to Melbourne in October 2006\, immediately tak ing a position in the WEHI High-Throughput Chemical Screening (HTCS) Facil ity. In his current role\, Dr Lackovic is responsible for managing collabo rative research projects seeking lead-like molecules across a broad range of target classes and disease types\, developing novel techniques\, and re porting findings. In addition\, he is responsible for the HTCS Facility's high-content imaging capabilities.

\n


Recent publicatio ns include:
Croker et al. Fas-mediated neutrophil apoptosi s is accelerated by Bid\, Bak\, and Bax and inhibited by Bcl-2 and Mcl-1. Proc Natl AcadSci U S A. 2011 108:13135-40.
Lackovic K\, Parisot JP \, Sleebs N\, Baell JB\, Debien L\, Watson KG\, Curtis JM\,Handman E\, Str eet IP\, Kedzierski L. Inhibitors of Leishmania GDP-mannose pyrophosphoryl ase identified by high-throughput screening of small-molecule chemical lib rary. Antimicrob Agents Chemother. 2010 54:1712-9.

END:VEVENT END:VCALENDAR